Evidence map›Paper›PMID 36186205›Full record

ReviewWorld journal of clinical cases2022

COVID-19 and the cardiovascular system-current knowledge and future perspectives.

Dimitrios G Chatzis, Kalliopi Magounaki, Ioannis Pantazopoulos, Sonu Menachem Maimonides Bhaskar

Abstract readReview
In one paragraph

Review in World journal of clinical cases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Impact of New Onset Atrial Fibrillation in Hospitalized Patients with COVID-19. Results of the "ACO-VID" Registry.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Dimitrios G ChatzisMedical School, European University Cyprus, Nicosia 2404, Cyprus. dimitrioschatzis@yahoo.com.
Kalliopi MagounakiDepartment of Internal Medicine, KAT General Hospital, Athens 14561, Greece.
Ioannis PantazopoulosDepartment of Emergency Medicine, Faculty of Medicine, University of Thessaly, Larissa 41500, Greece.
Sonu Menachem Maimonides BhaskarNSW Brain Clot Bank, NSW Health Pathology, Sydney, NSW 2170, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The current coronavirus disease 2019 (COVID-19) pandemic has had devastating impact on populations around the world. The high mortality rates in patients with COVID-19 has been attributed to the influence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), its causative viral agent, on several physiological systems in human body, including the respiratory, cardiovascular, and neurological systems. There is emerging evidence on propensity of this virus to attack cardiovascular system. However, various pathophysiological mechanisms by which SARS-CoV-2 interacts with cardiovascular system and leads to high morbidity and mortality, including cardiovascular complications, are poorly understood. This mini review aims to provide an update on the current knowledge and perspectives on areas of future research.

Indexed as

Angiotensin-converting enzyme 2 receptorsCardiovascular manifestationsCOVID-19Therapies

Identifiers

PMID36186205
PMCPMC9516937

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.